Indispensable advancements regarding non-small cell lung cancer (NSCLC) treatment have been made in the last two decades [1]. The main NSCLC treatments include curative resection and chemotherapy. However, NSCLC prognosis remains poor, and the 5-year survival rate is low due to tumor recurrence and metastasis at high frequencies [2,3]. These challenges make it urgent to discover new biotherapeutic drugs for NSCLC diagnosis and identify efficient therapeutic targets.

In China, traditional Chinese medicine exhibits anticancer activity [[4], [5], [6]]. Hyperoside is a flavonol glycoside compound obtained from Hypericum perforatum and which is cultivated worldwide. The anti-oxidative, anti-inflammatory, analgesic, and anticancer effects of hyperoside were extensively investigated. Hyperoside can inhibit the growth of various malignancies such as lung cancer, colorectal cancer, ovarian cancer, renal cancer, pancreatic cancer, osteosarcoma, and prostate cancer with no serious side effects or drug resistance [[7], [8], [9], [10], [11], [12]].

However, the role of hyperoside inNSCLC was still unknown. Hence, this study was performed to reveal the role and regulatory mechanism of hyperoside in NSCLC progression.